$FULC
Fulcrum Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000156459021054234 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $5.058M $4.935M $1.848M
YoY Change 19.57% 167.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.705M $8.628M $5.310M
YoY Change 65.33% 62.49% 51.28%
% of Gross Profit
Research & Development $18.91M $17.08M $15.64M
YoY Change 17.1% 9.19% 15.89%
% of Gross Profit
Depreciation & Amortization $621.0K $600.0K $500.0K
YoY Change -14.93% 20.0% 0.0%
% of Gross Profit
Operating Expenses $28.62M $25.71M $20.95M
YoY Change 30.02% 22.69% 23.2%
Operating Profit -$20.77M -$19.10M
YoY Change 8.72% 12.34%
Interest Expense $54.00K $142.0K
YoY Change -61.97% -69.4%
% of Operating Profit
Other Income/Expense, Net $75.00K $54.00K $140.0K
YoY Change 7.14% -61.43% 1300.0%
Pretax Income -$23.48M -$20.72M -$18.96M
YoY Change 32.53% 9.26% 14.63%
Income Tax
% Of Pretax Income
Net Earnings -$23.48M -$20.72M -$18.96M
YoY Change 32.53% 9.25% 14.63%
Net Earnings / Revenue -464.29% -419.78% -1026.08%
Basic Earnings Per Share -$0.57
Diluted Earnings Per Share -$577.9K -$565.9K -$695.5K
COMMON SHARES
Basic Shares Outstanding 40.55M 36.61K
Diluted Shares Outstanding 36.61K

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $218.2M $240.3M $127.0M
YoY Change 93.21% 89.25% 25.0%
Cash & Equivalents $35.41M $65.47M $85.22M
Short-Term Investments $182.8M $174.9M $41.80M
Other Short-Term Assets $0.00 $38.00K $72.00K
YoY Change -100.0% -47.22% -76.39%
Inventory
Prepaid Expenses
Receivables $4.110M $1.558M $700.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $226.0M $246.2M $132.1M
YoY Change 89.1% 86.35% 25.56%
LONG-TERM ASSETS
Property, Plant & Equipment $7.368M $7.749M $8.395M
YoY Change -12.25% -7.7% -12.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $542.0K $519.0K $616.0K
YoY Change -6.23% -15.75% 944.07%
Total Long-Term Assets $9.002M $9.360M $10.10M
YoY Change -10.58% -7.35% -5.88%
TOTAL ASSETS
Total Short-Term Assets $226.0M $246.2M $132.1M
Total Long-Term Assets $9.002M $9.360M $10.10M
Total Assets $235.0M $255.5M $142.2M
YoY Change 81.36% 79.69% 22.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.788M $3.742M $3.634M
YoY Change 17.38% 2.97% -19.83%
Accrued Expenses $9.157M $10.20M $8.600M
YoY Change 27.18% 18.58% 145.71%
Deferred Revenue $13.61M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $19.20M $20.60M $26.50M
YoY Change -28.16% -22.28% 208.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.341M $10.80M
YoY Change -59.81% 13746.15%
Total Long-Term Liabilities $0.00 $4.341M $10.80M
YoY Change -100.0% -59.81% 13746.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.20M $20.60M $26.50M
Total Long-Term Liabilities $0.00 $4.341M $10.80M
Total Liabilities $23.46M $24.94M $37.20M
YoY Change -31.79% -32.96% 169.02%
SHAREHOLDERS EQUITY
Retained Earnings -$302.5M -$279.0M
YoY Change 36.48%
Common Stock $514.4M $509.7M
YoY Change 62.37%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares $0.00 $0.00 $0.00
Shareholders Equity $211.5M $230.6M $105.0M
YoY Change
Total Liabilities & Shareholders Equity $235.0M $255.5M $142.2M
YoY Change 81.36% 79.71% 22.63%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$23.48M -$20.72M -$18.96M
YoY Change 32.53% 9.25% 14.63%
Depreciation, Depletion And Amortization $621.0K $600.0K $500.0K
YoY Change -14.93% 20.0% 0.0%
Cash From Operating Activities -$21.86M -$22.57M -$4.500M
YoY Change 10.23% 401.62% -65.44%
INVESTING ACTIVITIES
Capital Expenditures -$519.0K -$367.0K -$90.00K
YoY Change 10.43% 307.78% -59.09%
Acquisitions
YoY Change
Other Investing Activities -$8.575M -$106.3M $14.18M
YoY Change -39.31% -849.43%
Cash From Investing Activities -$9.094M -$106.6M $14.09M
YoY Change -37.71% -856.82% -6504.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 891.0K 137.9M -80.00K
YoY Change -85.74% -172478.75% -100.12%
NET CHANGE
Cash From Operating Activities -21.86M -22.57M -4.500M
Cash From Investing Activities -9.094M -106.6M 14.09M
Cash From Financing Activities 891.0K 137.9M -80.00K
Net Change In Cash -30.06M 8.694M 9.510M
YoY Change 6.67% -8.58% -81.7%
FREE CASH FLOW
Cash From Operating Activities -$21.86M -$22.57M -$4.500M
Capital Expenditures -$519.0K -$367.0K -$90.00K
Free Cash Flow -$21.34M -$22.21M -$4.410M
YoY Change 10.22% 403.54% -65.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4674000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
519000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
578000
CY2020Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
7267000
CY2021Q3 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
469000
CY2020Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
469000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6131000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14910000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20597000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26725000
CY2021Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1642000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36606
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
87153000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
87000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1776000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18962000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
104985000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95181000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47407000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
93000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2073000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16999000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
127754000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
242000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2546000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19648000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
110890000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135451000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
2403000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2658000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-78000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20716000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
230609000
us-gaap Profit Loss
ProfitLoss
-57363000
us-gaap Profit Loss
ProfitLoss
-53099000
us-gaap Depreciation
Depreciation
1894000
us-gaap Depreciation
Depreciation
1646000
us-gaap Share Based Compensation
ShareBasedCompensation
7277000
us-gaap Share Based Compensation
ShareBasedCompensation
5673000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-287000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
103000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Entity Registrant Name
EntityRegistrantName
FULCRUM THERAPEUTICS, INC.
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
FULC
CY2020Q4 us-gaap Assets Current
AssetsCurrent
119510000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7749000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8397000
CY2021Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1168000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
55862000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2000000
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
531000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4065000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
246187000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Local Phone Number
LocalPhoneNumber
651-8851
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65473000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
25705000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
54000
dei Document Type
DocumentType
10-Q
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Assets
Assets
255547000
CY2020Q4 us-gaap Assets
Assets
129577000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8628000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20770000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18962000
us-gaap Net Income Loss
NetIncomeLoss
-57363000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Net Income Loss
NetIncomeLoss
-53099000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28067402
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27941566
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1848000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14105000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15640000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50789000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40548783
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57052000
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
174872000
CY2021Q3 us-gaap Liabilities
Liabilities
24938000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316775000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-87000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40525985
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509638000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
255547000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
230609000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40545949
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278983000
CY2020Q4 us-gaap Liabilities
Liabilities
34396000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4935000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4598000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17077000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53824000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5312000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20811000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15525000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
20952000
us-gaap Operating Expenses
OperatingExpenses
71600000
us-gaap Operating Expenses
OperatingExpenses
58422000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19104000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57495000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
142000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
132000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42897000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
725000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3742000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4079000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24621
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20716000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-78000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
70631000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.16
CY2021Q3 fulc Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
2699000
CY2020Q4 fulc Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
3051000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2971000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221620000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95181000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129577000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1649000
CY2021Q3 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
10255000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33603
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27261
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1693000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18962000
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
4000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20716000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-18452000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
525000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
5000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2204000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
134000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57448000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53068000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
286000
us-gaap Net Income Loss
NetIncomeLoss
-57363000
us-gaap Net Income Loss
NetIncomeLoss
-53099000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-78000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-50000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-85000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
31000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20794000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19012000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15685000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
122131000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42540000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
64210000
fulc Net Proceeds From Issuances Of Common Stock In Public Offerings
NetProceedsFromIssuancesOfCommonStockInPublicOfferings
182934000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
17000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
37000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2699000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
897000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
185616000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64877000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8421000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
637000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
592000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
570000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1126000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-59000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
557000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-203000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1590000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2745000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3442000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11750000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9574000
fulc Increase Decrease In Deferred Rent And Deferred Lease Incentive
IncreaseDecreaseInDeferredRentAndDeferredLeaseIncentive
-359000
fulc Increase Decrease In Deferred Rent And Deferred Lease Incentive
IncreaseDecreaseInDeferredRentAndDeferredLeaseIncentive
-277000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56620000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33829000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
181349000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
81270000
fulc Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
61968000
fulc Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
39600000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1194000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
870000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-120575000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11492000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58144000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97805000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66565000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86313000
us-gaap Interest Paid Net
InterestPaidNet
3000
fulc Public Offering Costs Unpaid
PublicOfferingCostsUnpaid
76000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
314000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65473000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85221000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66565000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86313000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
11.00
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
47400000
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7590000
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
19.00
CY2021Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
135500000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions. </p>
CY2021Q3 fulc Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2021Q3 fulc Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2021Q3 fulc Cash And Cash Equivalents Amortized Cost
CashAndCashEquivalentsAmortizedCost
65473000
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
65473000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174959000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
90000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
174872000
CY2021Q3 fulc Cash Equivalents And Marketable Securities Amortized Cost Basis
CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
240432000
CY2021Q3 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
3000
CY2021Q3 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
90000
CY2021Q3 fulc Cash Equivalents And Marketable Securities Fair Value Disclosure
CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
240345000
CY2020Q4 fulc Cash And Cash Equivalents Amortized Cost
CashAndCashEquivalentsAmortizedCost
57052000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57052000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55864000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55862000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Amortized Cost Basis
CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
112916000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
2000
fulc Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2021Q3 fulc Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
164200000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Fair Value Disclosure
CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
112914000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15578000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14515000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7829000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6118000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7749000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8397000
CY2021Q3 us-gaap Depreciation
Depreciation
600000
CY2020Q3 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
1900000
us-gaap Depreciation
Depreciation
1600000
CY2021Q3 fulc Prepaid Expenses
PrepaidExpenses
4009000
CY2020Q4 fulc Prepaid Expenses
PrepaidExpenses
3668000
CY2021Q3 fulc Prepaid Sign On Bonuses Subject To Vesting Provisions
PrepaidSignOnBonusesSubjectToVestingProvisions
237000
CY2020Q4 fulc Prepaid Sign On Bonuses Subject To Vesting Provisions
PrepaidSignOnBonusesSubjectToVestingProvisions
147000
CY2021Q3 us-gaap Interest Receivable
InterestReceivable
390000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
176000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
38000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
74000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4674000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4065000
CY2020Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
17000
CY2021Q3 fulc Accrued Restricted Stock Liability Current
AccruedRestrictedStockLiabilityCurrent
1000
CY2020Q4 fulc Accrued Restricted Stock Liability Current
AccruedRestrictedStockLiabilityCurrent
6000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
38000
CY2021Q3 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
10255000
CY2021Q3 fulc Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
5899000
CY2020Q4 fulc Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4082000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3126000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2928000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1172000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
196000
CY2020Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
7267000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders
CY2021Q3 fulc Number Of Common Stock Voting Rights
NumberOfCommonStockVotingRights
1
us-gaap Dividends
Dividends
0
CY2021Q3 fulc Shares Reserved For Conversion Of Preferred Stock And Future Issuance Of Common Stock
SharesReservedForConversionOfPreferredStockAndFutureIssuanceOfCommonStock
6271785
CY2020Q4 fulc Shares Reserved For Conversion Of Preferred Stock And Future Issuance Of Common Stock
SharesReservedForConversionOfPreferredStockAndFutureIssuanceOfCommonStock
5156962
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2658000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1776000
us-gaap Share Based Compensation
ShareBasedCompensation
7277000
us-gaap Share Based Compensation
ShareBasedCompensation
5673000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M6D
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
597000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2424000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2497000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2572000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2649000
CY2021Q3 fulc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6966000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17705000
fulc Defined Contribution Plan Name
DefinedContributionPlanName
401(k)
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4982833
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3049906
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4982833
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3049906

Files In Submission

Name View Source Status
0001564590-21-054234-index-headers.html Edgar Link pending
0001564590-21-054234-index.html Edgar Link pending
0001564590-21-054234.txt Edgar Link pending
0001564590-21-054234-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fulc-10q_20210930.htm Edgar Link pending
fulc-10q_20210930_htm.xml Edgar Link completed
fulc-20210930.xsd Edgar Link pending
fulc-20210930_cal.xml Edgar Link unprocessable
fulc-20210930_def.xml Edgar Link unprocessable
fulc-20210930_lab.xml Edgar Link unprocessable
fulc-20210930_pre.xml Edgar Link unprocessable
fulc-ex101_13.htm Edgar Link pending
fulc-ex311_9.htm Edgar Link pending
fulc-ex312_10.htm Edgar Link pending
fulc-ex321_6.htm Edgar Link pending
fulc-ex322_7.htm Edgar Link pending
gnmwj5glr14o000001.jpg Edgar Link pending
gnmwj5glr14o000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending